TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg

Executive Summary

• TempraMed Technologies Ltd. announced a strategic distribution partnership with Salomo Executive to launch its VIVI product portfolio across the Benelux region and broader Western Europe.
• The collaboration leverages Salomo’s extensive healthcare logistics network, including over 500 pharmacy locations, medical wholesalers, and e‑commerce channels, to accelerate market penetration of TempraMed’s temperature‑controlled medication solutions.
• The partnership supports TempraMed’s growth strategy amid rising diabetes prevalence in the Netherlands, positioning the company for increased sales and brand visibility in a high‑growth market.

Key Details

• Partnership Scope: Distribution of TempraMed’s VIVI products (e.g., VIVI Cap, VIVI Epi) through Salomo Executive’s network of brick‑and‑mortar pharmacies, medical distributors, and diabetes‑focused webshops in the Benelux region.
• Geographic Focus: Western Europe, primarily Netherlands, Belgium, and Luxembourg.
• Salomo Executive Credentials: Provides last‑mile delivery for major pharma brands (e.g., Merck & Co.), operates >500 pharmacy locations, and offers e‑commerce and direct‑to‑consumer expertise.
• Market Opportunity: Approximately 1.2 million people with diabetes and 1.3 million with prediabetes in the Netherlands, driving demand for reliable temperature‑controlled storage solutions.
• Strategic Rationale (CEO Quote): “This partnership marks an important step in our broader expansion across Europe… we look forward to building a long‑term partnership that will accelerate access to TempraMed’s innovative solutions.” – Ron Nagar, CEO, TempraMed.
• Product Portfolio: Patented, FDA‑registered temperature‑regulated devices that operate without batteries or external power; includes VIVI Cap and VIVI Epi.
• Intellectual Property: Eight international patents supporting the technology platform.

Notable Quotes

“We are thrilled to collaborate with Salomo Executive, whose deep expertise in healthcare logistics and omnichannel distribution aligns perfectly with TempraMed's global growth strategy.” – Ron Nagar, CEO, TempraMed

Materiality Assessment: Material – Positive (the partnership is a significant commercial development that could materially enhance revenue and market reach).